Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2012, 5(6), 553-590; doi:10.3390/ph5060553
Review

Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications

1,* , 1
 and 2
Received: 17 April 2012; in revised form: 18 May 2012 / Accepted: 23 May 2012 / Published: 4 June 2012
(This article belongs to the Special Issue Gene Therapy)
View Full-Text   |   Download PDF [442 KB, uploaded 4 June 2012]   |   Browse Figures
Abstract: The pharmaceutical industry’s development of therapeutic medications for the treatment of Parkinson’s disease (PD) endures, as a result of the continuing need for better agents, and the increased clinical demand due to the aging population. Each new drug offers advantages and disadvantages to patients when compared to other medical offerings or surgical options. Deep brain stimulation (DBS) has become a standard surgical remedy for the effective treatment of select patients with PD, for whom most drug regimens have failed or become refractory. Similar to DBS as a surgical option, gene therapy for the treatment of PD is evolving as a future option. In the four different PD gene therapy approaches that have reached clinical trials investigators have documented an excellent safety profile associated with the stereotactic delivery, viral vectors and doses utilized, and transgenes expressed. In this article, we review the clinically relevant gene therapy strategies for the treatment of PD, concentrating on the published preclinical and clinical results, and the likely mechanisms involved. Based on these presentations, we advance an analysis of how the nature of the gene therapy used may eventually expand the scope and utility for the management of PD.
Keywords: convection-enhanced delivery; enzyme-replacement therapy; gene therapy; neurotrophic factor; Parkinson’s disease; viral vector convection-enhanced delivery; enzyme-replacement therapy; gene therapy; neurotrophic factor; Parkinson’s disease; viral vector
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Fiandaca, M.S.; Bankiewicz, K.S.; Federoff, H.J. Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications. Pharmaceuticals 2012, 5, 553-590.

AMA Style

Fiandaca MS, Bankiewicz KS, Federoff HJ. Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications. Pharmaceuticals. 2012; 5(6):553-590.

Chicago/Turabian Style

Fiandaca, Massimo S.; Bankiewicz, Krystof S.; Federoff, Howard J. 2012. "Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications." Pharmaceuticals 5, no. 6: 553-590.



Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert